Fifteen questions were formulated in relation, among others, to: (i) current and future injury prevention behaviour; (ii) needs and support for the intervention; (iii) characteristics (content, form) of the intervention; and (iv) strategies to deliver the intervention.
Our findings of biological activity of the TMZ/BV regimen in the upfront setting provide support for phase III randomized controlled trials investigating the use of this and other therapy combinations.
In the present study we find strong support for clades III and V, although branching order varied depending on the multigenic tree.
And also in 2010, the G-20 nations meeting in Seoul, Korea, expressed their support for Basel III.
At first a settlement was impossible because of Henry's support for Clement III, who had died in 1100.
When the dataset was reduced by removing the fast-evolving (long-branch) Ostreococcus tauri PSBS and the PSBS-like sequences from V. carteri and C. reinhardtii, as well as the divergent LHCz and FCP sequences, the percentage of unresolved quartets strongly decreased and the support for the clustering of helices I and III was further improved (99.8% versus 0.2%, Additional file 1, Figure S4A).
To identify spurious clades resulting from adaptive convergence in morphological characters, we followed the criteria proposed by Wiens, Chippindale & Hillis (2003): (i) evidence that the clade is incorrect (e.g. clade not recovered in the reference phylogeny); (ii) support for the clade based on morphology; and (iii) ecological relevance of the incorrect clade.
Three general themes were abstracted from the data reflecting their beliefs about the usefulness of the Reaching Out manual: (i) promoting carers' well-being, (ii) increasing carers' understanding of and support for the young person with FEP, and (iii) accessibility and delivery modes of the programme.
Moreover, the results of the CRYSTAL phase III study provide support for the use of the combination of FOLFIRI (5-fluorouracil/leucovorin/irinotecan) and cetuximab in the neoadjuvant setting and allow for R0 surgical resection with curative intent.
Thus, a key issue is whether to use the company as a platform for growth a substage III-G company—or as a means of support for the owners as they completely or partially disengage from the company—making it a substage III-D company.
These data provide support for the evaluation of empagliflozin as a treatment for type 2 diabetes in phase III trials.
